Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study
P Jong, S Yusuf, MF Rousseau, SA Ahn, SI Bangdiwala - The Lancet, 2003 - thelancet.com
Background In the studies of left ventricular dysfunction (SOLVD), enalapril reduced
mortality in patients with symptomatic but not asymptomatic left ventricular systolic …
mortality in patients with symptomatic but not asymptomatic left ventricular systolic …
Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion
B Zhu, Y Sun, RE Sievers, AEM Browne… - Journal of the American …, 2000 - jacc.org
OBJECTIVES We sought to assess the comparative effects of pretreatment with captopril
and losartan on myocardial infarct size and arrhythmias in a rat model of ischemia …
and losartan on myocardial infarct size and arrhythmias in a rat model of ischemia …
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial …
LH Lindholm, H Ibsen, B Dahlöf, RB Devereux… - The Lancet, 2002 - thelancet.com
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular
disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we …
disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we …
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience
M Pfisterer, JL Cox, CB Granger, SJ Brener… - Journal of the American …, 1998 - jacc.org
Objectives. We assessed the use and effects of acute intravenous and later oral atenolol
treatment in a prospectively planned post hoc analysis of the GUSTO-I dataset. Background …
treatment in a prospectively planned post hoc analysis of the GUSTO-I dataset. Background …
Omapatrilat-the story of Overture and Octave
AJS Coats - International journal of cardiology, 2002 - Elsevier
At the American College of Cardiology in March two major trials were presented. The
publicity surrounding the two could not have been more different. The LIFE demonstrated …
publicity surrounding the two could not have been more different. The LIFE demonstrated …
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
S Julius, SE Kjeldsen, M Weber, HR Brunner, S Ekman… - The Lancet, 2004 - thelancet.com
Summary Background The Valsartan Antihypertensive Long-term Use Evaluation (VALUE)
trial was designed to test the hypothesis that for the same blood-pressure control, valsartan …
trial was designed to test the hypothesis that for the same blood-pressure control, valsartan …
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Background Patients with chronic heart failure (CHF) are at high risk of cardiovascular death
and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin …
and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin …